Europe’s Big Pharma Players Begin Tricky 2022 In Style
Executive Summary
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.
You may also be interested in...
Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
D-Day Approaches For Bayer’s Asundexian Phase III Plans
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.